3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Glioblastoma
203
Brain Neoplasms
94
Gliosarcoma
93
Glioma
88
Central Nervous System Neoplasms
78
Astrocytoma
66
Oligodendroglioma
45
Melanoma
37
Medulloblastoma
18
Neuroblastoma
17
Neoplasm Metastasis
14
Ependymoma
13
Neoplasms
10
Choroid Plexus Neoplasms
10
Sarcoma
9
Recurrence
9
Optic Nerve Glioma
9
Familial ependymoma
9
Carcinoma, Non-Small-Cell Lung
9
Ovarian Neoplasms
8
Lung Neoplasms
8
Spinal Cord Neoplasms
7
Breast Neoplasms
7
Uveal Melanoma
6
Sarcoma, Ewing
6
Rhabdoid Tumor
6
Pinealoma
6
Neuroectodermal Tumors, Primitive
6
Unspecified Adult Solid Tumor, Protocol Specific
5
Small Cell Lung Carcinoma
5
Interventions
Cyclophosphamide
110
fludarabine phosphate
106
Busulfan
84
Azacitidine
73
Peripheral Blood Stem Cell Transplantation
64
Mycophenolic Acid
64
Antilymphocyte Serum
64
Cytarabine
63
Tacrolimus
62
fludarabine
61
Cyclosporine
56
Filgrastim
55
Whole-Body Irradiation
52
Methotrexate
47
Melphalan
42
Decitabine
42
Radiotherapy
37
Clofarabine
29
Granulocyte Colony-Stimulating Factor
28
Cord Blood Stem Cell Transplantation
28
Methylprednisolone
24
Etoposide
24
thymoglobulin
21
Thiotepa
21
Stem Cell Transplantation
21
sargramostim
19
Sirolimus
16
Alemtuzumab
15
Lenalidomide
13
Gemtuzumab
13
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Myelodysplastic Syndromes
×
Temozolomide
×
Clear all
NCT00687323
2017-06-07
TALL
Merck Sharp & Dohme LLC
Phase 2
Completed
47 enrolled
12 charts